Annual SG&A
$71.81 M
+$10.72 M+17.55%
31 December 2023
Summary:
Adaptimmune Therapeutics annual selling, general & administrative expenses is currently $71.81 million, with the most recent change of +$10.72 million (+17.55%) on 31 December 2023. During the last 3 years, it has risen by +$26.02 million (+56.81%). ADAP annual SG&A is now at all-time high.ADAP Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$21.28 M
+$2.19 M+11.50%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly selling, general & administrative expenses is currently $21.28 million, with the most recent change of +$2.19 million (+11.50%) on 30 September 2024. Over the past year, it has increased by +$5.11 million (+31.63%). ADAP quarterly SG&A is now at all-time high.ADAP Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$4.12 B
-$44.52 M-1.09%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM selling, general & administrative expenses is currently -$4.12 billion, with the most recent change of -$44.52 million (-1.09%) on 30 September 2024. Over the past year, it has dropped by -$4.18 billion (-6167.29%). ADAP TTM SG&A is now -12659.97% below its all-time high of $76.97 million, reached on 30 September 2024.ADAP TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.6% | +31.6% | -6167.3% |
| 3 y3 years | +56.8% | +40.2% | -7482.1% |
| 5 y5 years | +64.7% | +98.1% | -9568.6% |
ADAP Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +56.8% | at high | +64.7% | -59.8% | at low |
| 5 y | 5 years | at high | +65.5% | at high | +129.8% | -178.6% | at low |
| alltime | all time | at high | +5826.9% | at high | +1402.2% | <-9999.0% | at low |
Adaptimmune Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $21.28 M(+11.5%) | $76.97 M(+7.1%) |
| June 2024 | - | $19.08 M(-3.3%) | $71.86 M(-1.4%) |
| Mar 2024 | - | $19.73 M(+16.9%) | $72.85 M(+1.4%) |
| Dec 2023 | $71.81 M(+17.5%) | $16.88 M(+4.4%) | $71.81 M(+5.8%) |
| Sept 2023 | - | $16.16 M(-19.5%) | $67.85 M(-1.0%) |
| June 2023 | - | $20.07 M(+7.4%) | $68.50 M(+8.8%) |
| Mar 2023 | - | $18.69 M(+44.7%) | $62.98 M(+3.1%) |
| Dec 2022 | $61.09 M(+6.6%) | $12.92 M(-23.2%) | $61.09 M(-2.9%) |
| Sept 2022 | - | $16.82 M(+15.6%) | $62.95 M(+2.7%) |
| June 2022 | - | $14.55 M(-13.4%) | $61.30 M(+1.7%) |
| Mar 2022 | - | $16.80 M(+13.7%) | $60.29 M(+5.2%) |
| Dec 2021 | $57.30 M(+25.1%) | $14.78 M(-2.6%) | $57.30 M(+2.8%) |
| Sept 2021 | - | $15.17 M(+12.1%) | $55.77 M(+4.1%) |
| June 2021 | - | $13.54 M(-2.0%) | $53.59 M(+6.4%) |
| Mar 2021 | - | $13.82 M(+4.4%) | $50.35 M(+9.9%) |
| Dec 2020 | $45.80 M(+5.5%) | $13.24 M(+1.8%) | $45.80 M(+5.8%) |
| Sept 2020 | - | $13.00 M(+26.3%) | $43.29 M(+5.5%) |
| June 2020 | - | $10.29 M(+11.2%) | $41.03 M(+0.4%) |
| Mar 2020 | - | $9.26 M(-13.7%) | $40.88 M(-5.8%) |
| Dec 2019 | $43.39 M | $10.73 M(-0.1%) | $43.39 M(-0.2%) |
| Sept 2019 | - | $10.74 M(+5.8%) | $43.48 M(+1.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $10.15 M(-13.8%) | $43.03 M(-2.6%) |
| Mar 2019 | - | $11.77 M(+8.8%) | $44.17 M(+1.3%) |
| Dec 2018 | $43.60 M(+40.2%) | $10.82 M(+5.1%) | $43.60 M(+4.8%) |
| Sept 2018 | - | $10.29 M(-8.9%) | $41.61 M(+5.5%) |
| June 2018 | - | $11.29 M(+0.8%) | $39.43 M(+10.0%) |
| Mar 2018 | - | $11.20 M(+27.0%) | $35.85 M(+15.2%) |
| Dec 2017 | $31.11 M(+34.0%) | $8.82 M(+8.8%) | $31.11 M(+8.7%) |
| Sept 2017 | - | $8.11 M(+5.2%) | $28.63 M(+10.4%) |
| June 2017 | - | $7.71 M(+19.3%) | $25.94 M(+6.3%) |
| Mar 2017 | - | $6.46 M(+1.9%) | $24.40 M(+5.2%) |
| Dec 2016 | $23.21 M(+134.0%) | $6.34 M(+17.0%) | $23.21 M(+37.6%) |
| Sept 2016 | - | $5.42 M(-12.1%) | $16.86 M(+3.4%) |
| June 2016 | - | $6.17 M(+17.2%) | $16.31 M(+60.9%) |
| Mar 2016 | - | $5.27 M(+8.0%) | $10.14 M(+61.2%) |
| Dec 2015 | $9.92 M(-4.4%) | - | - |
| Sept 2015 | - | $4.88 M(+244.2%) | $6.29 M(+93.7%) |
| June 2015 | $10.38 M(+274.4%) | - | - |
| Dec 2014 | - | $1.42 M(-22.7%) | $3.25 M(+77.3%) |
| Sept 2014 | - | $1.83 M | $1.83 M |
| June 2014 | $2.77 M(+128.7%) | - | - |
| June 2013 | $1.21 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual SG&A year-on-year change?
- What is Adaptimmune Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly SG&A year-on-year change?
- What is Adaptimmune Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM SG&A year-on-year change?
What is Adaptimmune Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of ADAP is $71.81 M
What is the all time high annual SG&A for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual selling, general & administrative expenses is $71.81 M
What is Adaptimmune Therapeutics annual SG&A year-on-year change?
Over the past year, ADAP annual selling, general & administrative expenses has changed by +$10.72 M (+17.55%)
What is Adaptimmune Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of ADAP is $21.28 M
What is the all time high quarterly SG&A for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly selling, general & administrative expenses is $21.28 M
What is Adaptimmune Therapeutics quarterly SG&A year-on-year change?
Over the past year, ADAP quarterly selling, general & administrative expenses has changed by +$5.11 M (+31.63%)
What is Adaptimmune Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of ADAP is -$4.12 B
What is the all time high TTM SG&A for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM selling, general & administrative expenses is $76.97 M
What is Adaptimmune Therapeutics TTM SG&A year-on-year change?
Over the past year, ADAP TTM selling, general & administrative expenses has changed by -$4.18 B (-6167.29%)